Explore News By Topic

03/18/2020

KRISTEN BELL SELECTS THE WINNERS OF THE PROSTATE CANCER FOUNDATION’S 3RD ANNUAL TRUE LOVE CONTEST

LOS ANGELES, Calif., March 18, 2020 – The Prostate Cancer Foundation (PCF) and actress Kristen Bell announced today, the winners of the 3rd Annual TRUE Love Contest that honors caregivers and supporters of prostate cancer patients. From more than a hundred inspirational stories, Bell chose two heartfelt stories – one... Read More

02/13/2020

Cleveland Clinic Researchers Validate Link Between Genetic Variant and Poor Outcomes in Men with Advanced Prostate Cancer

February 13, 2020, CLEVELAND: In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that the a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the... Read More

02/04/2020

THE PROSTATE CANCER FOUNDATION RECRUITS NBA AND NHL TEAMS TO JOIN FORCES FOR THE 2ND ANNUAL PCF BLACK HISTORY MONTH ASSIST CHALLENGE

LOS ANGELES, Calif., February 4, 2020 – The Prostate Cancer Foundation (PCF) has drafted teams from the NBA and NHL to help fight prostate cancer with the 2nd Annual PCF Black History Month Assist Challenge. Teams participating during February include Atlanta Hawks, Brooklyn Nets, Chicago Bulls, Detroit Pistons, Indiana Pacers,... Read More

01/29/2020

THE PROSTATE CANCER FOUNDATION AND KRISTEN BELL HONOR CAREGIVERS WITH ITS 3RD ANNUAL TRUE LOVE CONTEST

LOS ANGELES, Calif., January 29, 2020 – Beginning February 1st, the Prostate Cancer Foundation (PCF) will launch its 3rd Annual TRUE Love contest to honor family and caregivers for their diligent work in caring for their loved ones living with prostate cancer. TRUE pays tribute to the unsung heroes –... Read More

12/16/2019

FDA approves enzalutamide for metastatic castration-sensitive prostate cancer

December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded... Read More

12/16/2019

Winship study sheds light on immune control of cancer

Issued by: Emory University Woodruff Health Sciences Center New findings could provide doctors with vital clues about how the immune system prevents cancer from recurring. The study from Winship Cancer Institute of Emory University looked at whether immune cells were present in tumor samples removed from patients with kidney and... Read More

11/11/2019

The Prostate Cancer Foundation Adds Four New Centers Of Excellence To Serve And Honor Veterans With Prostate Cancer

LOS ANGELES, Calif., Nov. 11, 2019 /PRNewswire/ -- Four new Prostate Cancer Foundation (PCF) Centers of Excellence (COEs) have joined the PCF's dedicated network of centers executing the ambitious mission of improving the care for U.S. Veterans with prostate cancer. With the addition of the new centers, the PCF has established 10 COEs... Read More

10/22/2019

Results of the CARD trial: Benefit for patients needing a third-line therapy option

Metastatic castration-resistant prostate cancer (mCRPC) refers to prostate cancer that has spread outside the prostate and no longer responds to traditional androgen deprivation therapy (ADT). Patients have several different treatment options, including second-generation androgen-signaling-targeted inhibitors (ARTA) like abiraterone or enzalutamide, and chemotherapy drugs (docetaxel, cabazitaxel). However, for patients whose disease... Read More

10/15/2019

Artificial Intelligence and Prostate Cancer Diagnosis

The field of artificial intelligence (AI) started in the 1950’s in the defense industry, and has evolved over the years. In the 2010s, new computer-based “deep-learning” methods were introduced that significantly accelerated the field. Physician-scientists are using this technology in the medical field to improve diagnostic methods. One such researcher... Read More

10/01/2019

Studying the Effects of ADT on Brain Function

Androgen deprivation therapy (ADT) is a primary treatment for prostate cancer, and acts by blocking the production or action of testosterone and other male hormones that activate the androgen receptor (AR). Studies have suggested that ADT may affect cognition and has been associated with the development of Alzheimer’s disease and... Read More